Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

A Genome-Wide Synthetic Lethal Screen Identifies Spermidine Synthase as a Target to Enhance Erdafitinib Efficacy in FGFR-Mutant Bladder Cancer.

Cancer research - 16 Jun 2025

Yu Yanchao, Gao Xincheng, Zhao Huayuan, Sun Jiayin, Wang Miao, Xiong Xing, Li Junping, Huang Chao, Zhang Hui, Jiang Guosong, Xiao Xingyuan

Abstract excerpt

Mutations of the FGFR family members are frequently observed in metastatic bladder cancer. The development of erdafitinib, a pan-FGFR inhibitor, provided a significant therapeutic advance in bladder cancer, but resistance still limits its efficacy. In this study, we performed an unbiased whole-genome CRISPR-Cas9 synthetic lethal screen on FGFR-mutant bladder cancer cell lines treated with erdafitinib and...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to CRISPR-Cas Systems
Share to Peptide Initiation Factors

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Pyrazoles

Share to Quinoxalines

Share to Receptors, Fibroblast Growth Factor

Share to Synthetic Lethal Mutations

Share to Urinary Bladder Neoplasms

Share to Xenograft Model Antitumor Assays

Source

Open in PubMed Open full text

Identifiers

PMID: 40126530
DOI: 10.1158/0008-5472.CAN-24-3217
PMCID: PMC12167931

Genes

SRM
EGFR
HMGA2

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

A Genome-Wide Synthetic Lethal Screen Identifies Spermidine Synthase as a Target to Enhance Erdafitinib Efficacy in FGFR-Mutant Bladder Cancer.PMID 40126530Read ↗

Engineered MED12 mutations drive leiomyoma-like transcriptional and metabolic programs by altering the 3D genome compartmentalization.Semantic proximity Read ↗

Engineered MED12 mutations drive uterine fibroid-like transcriptional and metabolic programs by altering the 3D genome compartmentalizationSemantic proximity Read ↗

Metabolic CRISPR screening identifies RPE as a key regulator of acquired enzalutamide resistance through FKBP5 destabilization in prostate cancer.Semantic proximity Read ↗

Polyamine and EIF5A hypusination downstream of c-Myc confers targeted therapy resistance in BRAF mutant melanoma.Semantic proximity Read ↗

Targeting FGFR in bladder cancer: ready for clinical practice?Semantic proximity Read ↗

LSD1/PRMT6-targeting gene therapy to attenuate androgen receptor toxic gain-of-function ameliorates spinobulbar muscular atrophy phenotypes in flies and mice.Semantic proximity Read ↗

A Role for De Novo Purine Metabolic Enzyme PAICS in Bladder Cancer ProgressionSemantic proximity Read ↗

CRISPR/Cas9 genome-wide loss-of-function screening identifies druggable cellular factors involved in sunitinib resistance in renal cell carcinomaSemantic proximity Read ↗

Difluoromethylornithine rebalances aberrant polyamine ratios in Snyder-Robinson syndrome: mechanism of action and therapeutic potentialSemantic proximity Read ↗

Combined CRISPRi/a-Based Chemical Genetic Screens Reveal that Rigosertib Is a Microtubule-Destabilizing Agent.Semantic proximity Read ↗

Spermine synthase and MYC cooperate to maintain colorectal cancer cell survival by repressing Bim expressionSemantic proximity Read ↗

HRAS as a potential therapeutic target of salirasib RAS inhibitor in bladder cancer.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.